Epirus’ Remicade biosimilar receives final approvals in India

September 18, 2014 11:04 AM

EPIRUS Biopharmaceuticals, Inc. announced that it has received final marketing and manufacturing approvals for its Remicade (infliximab) biosimilar, BOW015, from the Drug Controller General of India (DCGI). BOW015 is the first infliximab biosimilar approved in India.

“With these final clearances, we are now able to deliver a high quality product to patients who may not be able to afford current treatment options,” said Amit Munshi, president and CEO of EPIRUS. “We also intend to leverage this clinical data package to support additional regulatory filings in targeted global markets.”

BOW015 is a biosimilar to Remicade, which is marketed globally for the treatment of inflammatory diseases including rheumatoid arthritis, Crohn’s Disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis and psoriasis. BOW015 will be manufactured by Reliance Life Sciences at a facility in Mumbai which was inspected and approved in July of this year. The DCGI has issued the final clearances for BOW015, and EPIRUS and its commercialization partner Ranbaxy Laboratories Limited (Ranbaxy) expect to launch the drug, under the brand name Infimab®, by the first quarter of 2015.

“We believe that the data supporting BOW015’s clinical comparability to Remicade, presented earlier this year at the EULAR meeting in Paris, combined with EPIRUS’ focus on emerging markets, will help expand patient access to this important medicine,” added Jonathan Kay, M.D., professor of medicine and director of clinical research in the division of rheumatology at UMass Memorial Medical Center and the University of Massachusetts Medical School. Dr. Kay serves as a clinical advisor to EPIRUS.

Ranbaxy and EPIRUS signed a licensing agreement for BOW015 in January of 2014. Under the terms of the agreement, EPIRUS will develop and supply BOW015, and Ranbaxy will register and commercialize BOW015 in India as well as in other territories in Southeast Asia, North Africa, and selected other markets.

 

Source: Epirus press release

1 Comment

  • VITHALRAO KULKARNI

    Dear sir,
    It is very great news as after Remicade no biologic in indian market,My congratulations to Epirus Team,In india still research and is very essential as millions of people are suffering with artharitis,due to high pice they are not able to Remicade.
    Epirus start the product “Infimab” as soon as posible with nominal price.
    Company specify the price soon..

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!